Mujahid A. Rizvi, MD, MPH; Kiarash Kojouri, MD; James N. George, MD
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
Rizvi M., Kojouri K., George J.; Drug-Induced Thrombocytopenia: An Updated Systematic Review. Ann Intern Med. 2001;134:346. doi: 10.7326/0003-4819-134-4-200102200-00030
Download citation file:
Published: Ann Intern Med. 2001;134(4):346.
TO THE EDITOR:
We previously systematically reviewed all English-language reports, published up to 31 December 1997, on drug-induced thrombocytopenia (1). Our goal was to provide a database describing the level of evidence for a causal role for each drug and clinical outcomes (1). This letter describes our continuing systematic review for 2 subsequent years: 1 January 1998 to 31 December 1999. Through a MEDLINE literature search, we retrieved 58 articles; we identified 71 additional articles by searching the bibliographies of the retrieved articles. Thirty-five of the 71 additional articles had been published since 1966 but had not been identified in our previous MEDLINE literature search (1); 36 were published before 1966 but had not been identified in our previous search of bibliographies of retrieved articles (1). These articles contained 147 patient case reports, of which 78 were excluded because they did not meet previously defined criteria (1). The remaining 69 patient case reports involved 34 drugs. Nine drugs had level I (definite) evidence, and 17 other drugs had level II (probable) evidence. Of these 26 drugs, 15 had not been documented in the previous review as having definite or probable evidence for the drug as a cause of thrombocytopenia (1). Four of these 15 drugs each had one report with level I evidence; 11 drugs each had one report with level II evidence. The Table lists the four drugs with level I evidence and the two drugs for which the causal relation to thrombocytopenia was validated by at least two reports with level II evidence.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only